G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 100.6 INR -2.89% Market Closed
Market Cap: 134.9B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GLS stock under the Base Case scenario is 815.55 INR. Compared to the current market price of 1 100.6 INR, Glenmark Life Sciences Ltd is Overvalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLS Relative Value
Base Case
815.55 INR
Overvaluation 26%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

6.1
P/S
P/S
Price to Sales
6.1
vs History
6
vs Industry
22
Median 3Y
3.3
Median 5Y
3.3
Industry
2.4
Forward
5.5
More Details
31.8
P/E
P/E
Price to Earnings
31.8
vs History
6
vs Industry
14
Median 3Y
15.4
Median 5Y
15
Industry
20.5
Forward
27
More Details
32.3
P/OCF
P/OCF
Price to OCF
32.3
vs History
4
vs Industry
13
Median 3Y
22
Median 5Y
17.2
Industry
15.6
More Details
51.5
P/FCFE
P/FCFE
Price to FCFE
51.5
vs History
8
vs Industry
11
Median 3Y
34.2
Median 5Y
25.1
Industry
23.1
More Details
5.3
P/B
P/B
Price to Book Value
5.3
vs History
6
vs Industry
13
Median 3Y
3.4
Median 5Y
3.4
Industry
2
More Details
5.9
EV/S
EV/S
Enterprise Value to Sales
5.9
vs History
6
vs Industry
22
Median 3Y
3.2
Median 5Y
3
Industry
2.5
Forward
5.3
More Details
10.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.7
vs History
6
vs Industry
20
Median 3Y
5.8
Median 5Y
5.6
Industry
4.9
More Details
21.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21.3
vs History
6
vs Industry
17
Median 3Y
10.1
Median 5Y
9.8
Industry
12.3
Forward
18.4
More Details
23.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.6
vs History
6
vs Industry
19
Median 3Y
10.8
Median 5Y
10.5
Industry
15.5
Forward
21
More Details
31.1
EV/OCF
EV/OCF
Enterprise Value to OCF
31.1
vs History
4
vs Industry
14
Median 3Y
20.9
Median 5Y
16.1
Industry
14.1
More Details
48.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
48.9
vs History
8
vs Industry
10
Median 3Y
32.5
Median 5Y
23.4
Industry
17.5
More Details
6
EV/IC
EV/IC
Enterprise Value to IC
6
vs History
4
vs Industry
13
Median 3Y
3.7
Median 5Y
3.7
Industry
1.8
More Details

Multiples Across Competitors

GLS Competitors Multiples
Glenmark Life Sciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Glenmark Life Sciences Ltd
NSE:GLS
134.9B INR 6.1 31.8 21.3 23.6
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
191.1B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
IN
G
Glenmark Life Sciences Ltd
NSE:GLS
Average P/E: 24.4
31.8
15%
2.1
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
G
Glenmark Life Sciences Ltd
NSE:GLS
Average EV/EBITDA: 395.5
21.3
14%
1.5
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
G
Glenmark Life Sciences Ltd
NSE:GLS
Average EV/EBIT: 1 698.7
23.6
12%
2
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.6
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
GLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLS stock valuation using valuation multiples.
Wall Street Estimates
GLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.